Blue Bliss Pellets 80mg 5MAPB / 20mg 2FMA / 2mg 5-MeO-MiPT
€ 39,75 – € 590,00Price range: € 39,75 through € 590,00
Blue Bliss Pellets are described as a multi-component research preparation containing three named compounds: 5-MAPB, 2-FMA, and 5-MeO-MiPT.
These substances belong to different structural families: benzofuran derivatives, substituted amphetamines, and methoxylated tryptamines.
The supplied source describes compressed pellets with labeled component quantities of 80mg 5-MAPB, 20mg 2-FMA, and 2mg 5-MeO-MiPT per finished unit.
These quantities have not been independently verified by a finished-pellet assay.
The described research context includes chemical identity assessment, multi-analyte chromatographic characterization, spectral analysis, and investigation of analytical distinctions between the three named components.
The source reports separate CAS numbers and claims ingredient purity of at least 98% for each component.
It also refers to third-party testing, Certificates of Analysis, batch tracking, and ISO-compliant manufacturing.
No actual batch-specific analytical reports or manufacturing certifications were supplied.
Component identity, chemical forms, ingredient purity, finished-unit content, content uniformity, excipient composition, and storage stability remain unverified.
The preparation is not established as a certified reference material or validated quantitative calibration mixture.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Blue Bliss Pellets – 5-MAPB, 2-FMA & 5-MeO-MiPT Research Blend
Blue Bliss Pellets – Product Overview
Blue Bliss Pellets is the supplied catalog designation for a compressed-pellet research preparation associated with three named synthetic compounds: 5-MAPB, 2-FMA, and 5-MeO-MiPT.
The components belong to different chemical families and should be distinguished individually when describing the preparation. Blue Bliss Pellets
5-MAPB is a substituted benzofuran derivative.
2-FMA is an ortho-fluorinated methamphetamine analog belonging to the substituted amphetamine family.
5-MeO-MiPT is a methoxylated tryptamine derivative.
The source describes a single finished pellet containing labeled quantities of all three components.
These figures are source-provided specifications rather than independently confirmed analytical measurements.
No finished-unit assay, component-specific quantitative report, or content-uniformity study accompanied the information.
The source positions the preparation for controlled analytical and non-clinical laboratory research.
The stated scientific contexts include chemical identification, chromatographic characterization, spectral differentiation, and investigation of multi-component analytical systems.
These potential research contexts should not be confused with verified analytical performance of the actual finished pellets.
The supplied information also refers to independent testing, batch records, and Certificate of Analysis documentation.
However, no supporting laboratory certificates or batch-specific analytical results were provided.
The finished preparation is not established as a certified reference material, validated quantitative calibration mixture, or approved pharmaceutical product. Blue Bliss Pellets Blue Bliss Pellets
Chemical Identity & Classification
Blue Bliss is a product designation for a mixture rather than the name of a single chemical substance.
Accordingly, the finished preparation does not have one molecular formula, molecular weight, or CAS Registry Number that can be assigned from the supplied information.
The source identifies three individual components:
| Component | Chemical identity | Reported CAS number |
|---|---|---|
| 5-MAPB | 5-(2-Methylaminopropyl)benzofuran | 1354631-77-8 |
| 2-FMA | 2-Fluoromethamphetamine | 1017176-48-5 |
| 5-MeO-MiPT | 5-Methoxy-N-methyl-N-isopropyltryptamine | 96096-55-8 |
All three CAS numbers are source-provided and have not been independently verified against the actual ingredient forms.
The reported component quantities are:
- 5-MAPB: 80mg per pellet, labeled amount
- 2-FMA: 20mg per pellet, labeled amount
- 5-MeO-MiPT: 2mg per pellet, labeled amount
The combined labeled analyte quantity is 102mg per pellet.
This arithmetic total does not establish the actual finished-unit assay, total pellet mass, or ingredient distribution. Blue Bliss Pellets
The source does not identify whether each component is present as a neutral compound or a salt.
It also does not establish the stereochemical composition of the components where applicable.
These distinctions can affect chemical identifiers, molecular weights, analytical interpretation, and the relationship between labeled quantities and actual chemical composition.
The finished preparation may also contain additional formulation components, but no excipient specification was supplied.
Researchers may consult PubChem for public chemical-reference information, ensuring that each selected record corresponds to the relevant component structure, stereochemistry, and chemical form.
Chemical & Physical Characteristics
The supplied source describes Blue Bliss as compressed pellets.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied. Blue Bliss Pellets
A compressed pellet is a finished preparation that may contain multiple analytes together with additional formulation components.
The source does not identify pellet dimensions, total unit mass, compression characteristics, excipient composition, or manufacturing method.
Because the preparation contains three different named compounds, its overall chemical characteristics cannot be represented by the properties of any single ingredient.
The source does not provide measured solubility, dissolution, stability, or analytical recovery data for the complete pellet matrix.
It also does not establish whether all three components are distributed uniformly within each finished unit.
The chemical forms of the individual components remain unverified.
Consequently, no definitive claim is made about the physical behavior of the finished mixture under particular laboratory conditions.
The reported presentation should be treated as a supplier-provided product description rather than an independently confirmed batch characteristic.
Purity & Analytical Verification
The supplied source claims purity of at least 98% for each of the three named components.
It also refers to independent analytical verification. Blue Bliss Pellets
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed component purities therefore remain unverified.
For Blue Bliss Pellets, ingredient purity and finished-unit composition are separate analytical characteristics.
Even independently verified ingredient-purity results would not, by themselves, establish the actual quantity of each analyte in the finished pellet.
Likewise, a nominal formulation ratio does not establish content uniformity across a batch.
The source mentions HPLC, GC-MS, LC-MS, and NMR spectroscopy as analytical techniques relevant to characterization.
However, it does not provide product-specific results demonstrating separation, identification, or quantitative recovery of the three components from the finished preparation.
No validated multi-analyte method, measurement-uncertainty statement, or assigned reference value was supplied.
The preparation should therefore not be described as a certified quantitative reference mixture.
Any definitive claims about purity, identity, composition, or uniformity require supporting analytical records for the actual batch.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, and ISO-compliant production conditions.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, or ISO certification was supplied.
The claims therefore remain unverified. Blue Bliss Pellets
For a three-component preparation, batch documentation should distinguish the identity and analytical characteristics of each named ingredient from the characteristics of the finished pellet.
The source does not establish whether the stated ingredient quantities were independently measured after formulation.
It also does not provide evidence of finished-unit content uniformity or batch-to-batch consistency.
For Blue Bliss Pellets, the distinction between nominal composition and verified finished-unit composition is particularly important because the three ingredients are chemically different.
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, ISO compliance, and batch consistency should be supported by actual records.
Safety, Handling & Laboratory Precautions
Blue Bliss is described as containing a benzofuran derivative, a substituted amphetamine, and a methoxylated tryptamine.
These chemical classes may present significant pharmacological and toxicological hazards.
The supplied source does not provide a complete toxicological assessment of the individual components or their combined preparation.
The presence of multiple active compounds also introduces uncertainty concerning combined hazards and unintended exposure.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed-pellet presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual component identities, chemical forms, purity values, and finished-unit contents have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes discreet packaging, batch-aware handling, tracking, and professional shipment arrangements. Blue Bliss Pellets
No actual packaging specification, container-validation report, or shipment-condition record was supplied.
The source recommends storage in a cool, dry environment protected from light.
It also suggests refrigeration at approximately 2–8°C.
No validated stability study was provided for the complete three-component pellet preparation.
The suggested temperature range therefore cannot be presented as a verified requirement or as evidence of a particular shelf life.
For Blue Bliss Pellets, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The component quantities should be recorded as labeled specifications unless independently verified.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
The supplied scientific context places Blue Bliss within analytical research involving multi-component chemical identification and differentiation of benzofuran, substituted amphetamine, and tryptamine derivatives.
The three named ingredients have distinct molecular structures and chemical classifications.
These distinctions are relevant to analytical documentation and the interpretation of chemical identity records.
The source describes interest in chromatographic characterization, forensic analytical studies, and investigation of complex chemical mixtures.
However, no product-specific analytical validation, combined pharmacological dataset, or stability study was supplied for the actual pellets.
The Raw Lab Chems catalog identifies Blue Bliss Pellets as the product listing discussed here.
For related multi-component catalog context, the supplied source also identifies Pink Star Pellets and MaXTC Blister.
These related listings describe different nominal formulations. Blue Bliss Pellets
In particular, the MaXTC designation identifies 4-FMA rather than 2-FMA as one of its named components.
The preparations should not be treated as chemically identical or analytically interchangeable.
The supplied information does not establish equivalent ingredient purity, finished-unit content, excipient composition, or content uniformity across these products.
These catalog references do not establish certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes professional packaging, international shipping, tracking, and secure handling arrangements.
No current inventory record, confirmed pack-size listing, carrier agreement, shipment authorization, or verified delivery information was supplied.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
The individual components may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
The combined preparation may also be subject to additional regulatory considerations.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Blue Bliss Pellets
Blue Bliss is described as a multi-component preparation containing 5-MAPB, 2-FMA, and 5-MeO-MiPT.
Possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation of these substances or their mixtures may be restricted or prohibited depending on the jurisdiction.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.